Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes-an Indian perspective

被引:68
作者
Aggarwal, Rohit [2 ]
Malaviya, Anand N. [1 ,3 ]
机构
[1] ISIC Superspecial Hosp, New Delhi 110070, India
[2] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[3] Indian Spinal Injury Ctr, New Delhi, India
关键词
Ankylosing spondylitis; Asians; Diagnosis delay; Factors; Outcome; NECROSIS-FACTOR-ALPHA; SCORING SYSTEM; DOUBLE-BLIND; BACK-PAIN; CRITERIA; DISEASE; INFLIXIMAB; INDEX; PLACEBO; TRIAL;
D O I
10.1007/s10067-008-1049-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study focuses on the causes and consequences of delay in diagnosis of ankylosing spondylitis (AS). Seventy consecutive patients presenting at a rheumatology clinic in India were studied. Mean (+/- S.D) delay in diagnosis was 6.9 (+/- 5.2) years. The main cause of delay was incorrect diagnosis as non-specific back pain (19/54, 35.1%), degenerative disc disease (14/54, 25.9%), rheumatoid arthritis (11/54, 20.37%), and tuberculosis of spine (9/54, 16.6%) in that order, for which the patient received prolonged treatment. Absence of extra-articular manifestations and juvenile age also significantly correlated with diagnostic delay. Delay in diagnosis resulted in significantly worse disease activity index (BASDAI), functional index (BASFI), and damage index (BASMI). Most incorrect initial diagnoses were made by orthopedicians (75.9%), followed by general physician (50%), and rheumatologist (12%). Continuing medical education workshops with a focus on clinical diagnosis of inflammatory back pain may help in early diagnosis of AS.
引用
收藏
页码:327 / 331
页数:5
相关论文
共 22 条
[1]  
Baraliakos X, 2008, SCAND J RHEUMATOL, V37, P33
[2]   Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis [J].
Brandt, J ;
Khariouzov, A ;
Listing, J ;
Haibel, H ;
Sörensen, H ;
Grassnickel, L ;
Rudwaleit, M ;
Sieper, J ;
Braun, J .
ARTHRITIS AND RHEUMATISM, 2003, 48 (06) :1667-1675
[3]   Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Golder, W ;
Gromica-Ihle, E ;
Kellner, H ;
Krause, A ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Thriene, W ;
Sieper, J .
LANCET, 2002, 359 (9313) :1187-1193
[4]   Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab - Evaluation of a new scoring system [J].
Braun, J ;
Baraliakos, X ;
Golder, W ;
Brandt, J ;
Rudwaleit, M ;
Listing, J ;
Bolow, M ;
Sieper, J ;
van der Heijde, D .
ARTHRITIS AND RHEUMATISM, 2003, 48 (04) :1126-1136
[5]  
CALIN A, 1988, J RHEUMATOL, V15, P1234
[6]  
CALIN A, 1994, J RHEUMATOL, V21, P2281
[7]   Primary care - Low back pain [J].
Deyo, RA ;
Weinstein, JN .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :363-370
[8]   Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria [J].
Dincer, Umit ;
Cakar, Engin ;
Kiralp, M. Zeki ;
Dursun, Hasan .
CLINICAL RHEUMATOLOGY, 2008, 27 (04) :457-462
[9]   Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis [J].
Feldtkeller, E ;
Khan, MA ;
van der Heijde, D ;
van der Linden, S ;
Braun, J .
RHEUMATOLOGY INTERNATIONAL, 2003, 23 (02) :61-66
[10]   Definition of disease duration in ankylosing spondylitis [J].
Feldtkeller, Ernst ;
Erlendsson, Jon .
RHEUMATOLOGY INTERNATIONAL, 2008, 28 (07) :693-696